21/01/2026 – AB Science today announced that the Japanese Patent Office has formally granted a patent for methods of treating progressive multiple sclerosis (MS) with its lead compound masitinib

07/01/2026 – AB Science today provides an update on the Phase 1 study of the molecule AB8939 and the fourth consecutive response with the combination of AB8939 + venetoclax in patients with acute myeloid leukemia

22/12/2025 – AB Science today announced that the United States Patent Office has formally granted a patent for methods of treating sickle cell disease using its lead compound masitinib, based on preclinical data

18/12/2025 – AB Science SA announces the initiation of coverage of its stock by Maxim Group, an independent US-based full-service investment bank, securities and wealth management firm

15/12/2025 – AB Science today announced the publication of a new AB8939 article on the preprint platform bioRxiv

11/12/2025 – AB Science today announced the publication of a new article on MedRxiv, presenting a post-hoc subgroup analysis of the phase 2b/3 AB10015 study